HSD3B1 Genotype Tied to Worse Outcomes in Low-Volume mCSPC
New findings suggest that the HSD3B1 genotype can be used to risk stratify white men with low-volume metastatic prostate cancer.
All articles by John Schieszer, MA
SABR Found to Improve Outcomes in Recurrent Oligometastatic HSPC
In patients with recurrent oligometastatic hormone-sensitive prostate cancer, stereotactic ablative radiation therapy decreased the risk of disease progression compared with observation alone, a phase 2 study found.
Genomic Alterations Linked to Outcomes in mCSPC
DNA sequencing in men with metastatic castration-sensitive prostate cancer revealed alterations in certain signaling pathways that predict worse overall survival and shorter progression time to castration-resistant disease.
Prostate MRI Improves Confirmatory Biopsy Sensitivity
MRI-guided confirmatory prostate biopsies more accurately detects grade progression among men on active surveillance for prostate cancer compared with TRUS-guided systematic biopsies alone.
AI Could Improve Prostate Cancer Brachytherapy
Enhanced deep-learning models have the potential to streamline prostate cancer brachytherapy treatment planning, according to investigators.
Imaging Needed to Identify Bone Metastases in Advanced PCa
Bone imaging cannot be safely omitted in advanced prostate cancer cases because no PSA level combined with T stage and Gleason Grade Group can accurately rule in bone metastases, a new study found.
Novel Antiandrogens and Cognitive Function
The authors of a recent review say they believe only a fraction of the men on androgen receptor-directed therapies who experience cognitive impairment report it.
Recognition, Diagnosis of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients Can Prevent Falls
A literature review identified CIPN as a potential contributor to falls and injuries in patients with cancer; however, evidence-based methods for preventing falls in these patients are scarce.
Prospective Study Characterizes PCa Risk Linked to BRCA1, BRCA2 Mutations
For decades, it has been known that the mutations in the tumor suppressor genes BRCA1 and BRCA2 are associated with high risks of breast and ovarian cancer, but a new prospective cohort study provides the strongest evidence to date that these mutations are associated with the development of prostate cancer (PCa). The BRCA2 mutation appears…
Sipuleucel-T Efficacy, Safety in mCRPC Evaluated in Real World Study
The median time from first infusion of sipuleucel-T to death from prostate cancer was 42.7 months.
- Loading...
Loading...
Next post in Prostate Cancer
Loading... 
Loading...